Pricing, Special

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

Takeda is about to buy its way to a number 1 spot in the top tier of drugmakers fielding the most expensive drugs on the planet.

Once its $62 billion Shire buyout goes through, Takeda will be responsible for selling three of the most expensive drugs on the market today, according to the latest list from GoodRx. And that's more than any other manufacturer on the ranking.

The drug pricing analysts at GoodRx decided this year that they needed to double the number of drugs tracked in order to be able to fully capture the growing ranks of therapies that command wholesale prices of more than $25,000 a month.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 41,700+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->